Roll no 1's assimilated single patient data linked below
Here is the 6-point CBME evaluation for *2023 Batch - Roll No. 1* - Portfolio: *31M, Farming and Vegetables Selling, Itchy Skin Lesions on Scalp - 1 Year, Right Half of Scalp*
Based on the anonymized text you pasted. Score 0-2 per level. Total /12.
### 1. Remember - Knowledge Recall
*Evidence in portfolio:*
- Demographics with occupation, chief complaints, HOPI, past history - Diagnosed Psoriasis 1 year ago, on medication - Folitrax 15 mg [on & off], Folvite 5 mg, Steron-S lotion, N/K/C/O HTN, DM, TB, Asthma, Epilepsy, no trauma, no surgery, no drug allergies, personal history - Occasional alcoholic, family history - H/O DM in father, general examination, PICCLE, O/E Cutaneous recorded.
- Good details: Pustules which later developed into plaques, associated with itchy lesion over scalp on right side, gradual and progressive in number.
- Gaps: No vitals - BP, PR, RR, Temp, SpO2 not recorded. No extent of plaques - size, number, nail changes, joint pain. No Koebner phenomenon, no triggers.
*Score: 2 / 2*
- Competency met: Systematic documentation, drug names + doses captured, cutaneous examination included.
### 2. Understand - Comprehension
*Evidence in portfolio:*
- Lesion evolution described - pustules to plaques, itchy, progressive.
- Cutaneous finding described - Multiple, Discrete, well defined, Greasy scales with plaques over scalp.
- But no explanation in own words of what psoriasis is - chronic immune-mediated, scaling, why plaques form. No explanation of why Folitrax / Folvite / Steron-S given.
- No explanation of why on & off medication matters.
*Score: 1 / 2*
- Partial comprehension.
- *Next target:* Explain: Psoriasis - immune-mediated chronic inflammation, increased keratinocyte turnover -> scaling + plaques. Explain: Folitrax = Methotrexate - immunosuppressant, Folvite = Folic acid - to reduce Methotrexate toxicity, Steron-S = topical steroid - to reduce inflammation / scaling. Explain: On & off Methotrexate = risk of flare + toxicity if not monitored.
### 3. Apply - Application to Patient Care
*Evidence in portfolio:*
- Diagnosis given as Psoriasis - already known case, consistent.
- No investigation plan, no management plan, no monitoring plan for Methotrexate.
- No application of occupation - farming / vegetables selling, sun exposure, trauma - to care.
*Score: 1 / 2*
- Partial application. Diagnosis stated, but not applied to safe follow-up care.
- *Next target:* Add: CBC, LFT, RFT for Methotrexate monitoring, PASI score, Nail examination, Joint examination for psoriatic arthritis. Add management - continue / counsel on regular Methotrexate, not on & off, Folic acid, topical steroids, moisturizer, avoid triggers - alcohol, smoking, stress, skin trauma, sun protection for farming work. Counsel on alcohol + Methotrexate = liver toxicity. Referral to Dermatology.
### 4. Analyze - Differentiation & Interpretation
*Evidence in portfolio:*
- No formal differential diagnosis listed.
- But clues for analysis present: Greasy scales, plaques, itchy, right scalp, pustules.
- No analysis of differentials: Seborrheic dermatitis - supports greasy scales, scalp, itchy; against - well-defined plaques, psoriasis history. Tinea capitis - supports scalp, itchy, farming; against - plaques with greasy scales, chronic 1 year. Eczema - supports itchy; against - discrete well-defined plaques.
- No analysis of why right half only - asymmetry not analyzed.
*Score: 1 / 2*
- Partial analysis - implicit, not explicit.
- *Next target:* Add differential table: Psoriasis - supports well-defined plaques, greasy scales, chronic, progressive, known case, on Methotrexate. Seborrheic dermatitis - supports greasy scales, scalp, itchy; against - less well-defined, less plaque. Tinea capitis - supports scalp lesion, farming exposure; against - no alopecia mentioned, chronic plaques. Use KOH / biopsy if doubtful. Must analyze pustules - pustular psoriasis vs secondary infection.
### 5. Evaluate - Judgment & Reflection
*Evidence in portfolio:*
- No justification for diagnosis, no reflection, no self-assessment.
- No discussion of Methotrexate safety - on & off use, occasional alcohol, no LFT monitoring, risk of liver toxicity.
- No counseling on chronic disease, adherence, psychosocial impact in 21M.
*Score: 0 / 2*
- Not met.
- *Next target:* Add: Why psoriasis and not seborrheic dermatitis / tinea? What is the risk of on & off Methotrexate + alcohol without LFT? What would I do differently - ask about joint pain, nail changes, family history of psoriasis, triggers, adherence reason? Reflection on chronic skin disease in young farmer - stigma, work, adherence.
### 6. Create - Synthesis & New Learning Product
*Evidence in portfolio:*
- No original product - no algorithm, concept map, patient education material.
*Score: 0 / 2*
- Not met.
- *Next target:* Create 1-page algorithm: Itchy Scaly Scalp Plaques -> Psoriasis vs Seborrheic Dermatitis vs Tinea -> Examination -> Investigations -> Management, OR patient education sheet for psoriasis - medication adherence, Methotrexate monitoring, triggers, skin care for farmer.
### Summary Sheet - Roll No. 1 - 2023 Batch
Bloom Level | Score /2 | Key Feedback
1. Remember | 2 | Good documentation, drug names + doses + cutaneous exam
2. Understand | 1 | Lesion described, psoriasis mechanism + drugs not explained
3. Apply | 1 | Diagnosis stated, no Methotrexate monitoring / management
4. Analyze | 1 | No explicit differential, pustules + greasy scales not analyzed
5. Evaluate | 0 | No justification, no Methotrexate safety judgment
6. Create | 0 | No original product
**Total** | **5 / 12** | **Needs Support - Developing**
*Overall CBME Feedback for Roll 1 - Portfolio:*
- *This portfolio = 5 / 12*
- *Strength:* Best drug history so far - Folitrax 15 mg on & off, Folvite 5 mg, Steron-S lotion all named. Cutaneous examination described in dermatology terms - discrete, well-defined, greasy scales, plaques.
- *Critical learning from this case:* Psoriasis is not just a skin diagnosis - Methotrexate + alcohol = liver risk. On & off Methotrexate is a red flag for adherence + toxicity. Next portfolio must add LFT / CBC monitoring and Analyze table to separate psoriasis from seborrheic dermatitis / tinea.
For patient centered CBME online learning portfolio assessment methodology details and further reading please click here: https://medicinedepartment.blogspot.com/2026/11/cbme-projr-six-point-evaluation-method.html?m=1

No comments:
Post a Comment